drugset / Trial / NCT05193201

A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

NCT05193201

Phase 1 Unknown 54 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the multiple-dose regimen of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.

Timeline

Start
2022-01-16
Primary completion
2022-10-16
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic 15000 iu Subcutaneous